Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck × budigalimab × 90 days × Clear all

NCT07241039 2026-02-17

A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT02988960 2026-01-09

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms